Scientists have developed a promising vitamin B12–based compound that could improve treatment for glioblastoma, one of the deadliest forms of brain cancer. In preclinical animal studies, the compound successfully crossed the blood-brain barrier and selectively accumulated inside glioblastoma tumors. It then released sustained levels of nitric oxide directly into cancer cells, helping to slow tumor growth. When combined with existing glioblastoma therapies, the treatment showed a powerful synergistic effect, significantly boosting anti-tumor activity compared to standard treatments alone. Although these findings are still limited to animal studies, they highlight a potential new strategy for delivering targeted therapies to hard-to-treat brain cancers.
Read more at ScienceDaily